MARKET

EIGR

EIGR

Eiger
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.48
-0.09
-0.78%
After Hours: 11.48 0 0.00% 16:41 11/15 EST
OPEN
11.67
PREV CLOSE
11.57
HIGH
11.78
LOW
11.23
VOLUME
111.33K
TURNOVER
--
52 WEEK HIGH
15.33
52 WEEK LOW
8.40
MARKET CAP
281.20M
P/E (TTM)
-3.4522
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EIGR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EIGR News

  • Eiger to Present at Jefferies 2019 London Healthcare Conference
  • PR Newswire.13h ago
  • Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
  • PR Newswire.3d ago
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.3d ago
  • Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy?
  • Insider Monkey.4d ago

More

Industry

Biotechnology & Medical Research
+1.35%
Pharmaceuticals & Medical Research
+1.27%

Hot Stocks

Name
Price
%Change

About EIGR

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
More

Webull offers Eiger Biopharmaceuticals Inc (EIGR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.